RxDoctor Payments Data

Malcolm Smith, MD

Pulmonary Disease · Texarkana, TXNPI 1174525174

Payments from drug & device makers

$12,646in general payments, 2019–2025

Across 466 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • GSK$1K
  • ZOLL Respicardia, Inc.$1K
  • Actelion Pharmaceuticals US, Inc.$928
  • United Therapeutics Corporation$874
  • Insmed, Inc.$804
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$1,79614%
  • Food & beverage$10,27581%
  • Education$5765%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,646 in reported general payments places this provider in the 75th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$424,071
Medicare patients
2,029
Services billed
4,531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate69$917,388
Trelegy ElliptaFluticasone/Umeclidin/Vilanter226$195,147
OpsumitMacitentan11$138,890
Pirfenidone13$116,149
Breztri AerosphereBudesonide/Glycopyr/Formoterol50$42,237
Tadalafil13$29,499
Stiolto RespimatTiotropium Br/Olodaterol Hcl44$26,295
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr46$24,242
Breo ElliptaFluticasone/Vilanterol47$20,526
Incruse ElliptaUmeclidinium Bromide28$12,427
Spiriva HandihalerTiotropium Bromide22$11,848
SymbicortBudesonide/Formoterol Fumarate34$10,737
Albuterol Sulfate HfaAlbuterol Sulfate227$6,303
Advair HfaFluticasone Propion/Salmeterol13$3,697
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$3,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat$647$943,683113 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$1,492$252,343347 claims
Actelion Pharmaceuticals US, Inc.Opsumit$928$138,89011 claims
AstraZenecaBreztri Aerosphere, Symbicort$678$52,97484 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Texarkana

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →